Summary sentence: Galectin-3 is cleaved by both neutrophils and bacteria and the residual galectin-3C inhibits galectin-3-induced neutrophil activity but potentiates galectin-3 cell-surface binding.
INTRODUCTION
Human neutrophils play a key role in the innate immune response to infection and aseptic tissue damage. These phagocytic cells circulate in a quiescent state in the blood stream until being recruited to sites of Abbreviations: CRD, carbohydrate recognition domain aa 114-250; ecROS, extracellularly released ROS; Fura 2-AM, fura-2-acetoxymethyl ester; galectin-3C, C-terminal fragment of galectin-3 containing the CRD but lacking the N-domain; icROS, intracellulary produced ROS; KRG, Krebs-Ringer phosphate buffer; MFI, geometric mean fluorescence intensity; MMPs, matrix metalloproteinases; NADPH-oxidase, nicotinamide adenine dinucleotide phosphate-oxidase; PFA, paraformaldehyde; PVDF, polyvinylidene difluoride; ROS, reactive oxygen species; RT, room temperature (∼20 • C); SOD, superoxide dismutase inflammation or infection in the tissue. During transmigration from the circulation into tissue, the neutrophil phenotype changes into a preactivated, primed state, associated with increased numbers of receptors on the cell surface and thus a greater capacity to respond to stimuli. 1, 2 One priming-dependent neutrophil activator is galectin-3, an endogenous lectin with the ability to stimulate production of reactive oxygen species (ROS) in neutrophils that have extravasated from blood into identified in mammals, defined by their sequence similarities in the 135 amino acid carbohydrate recognition domain (CRD). 7 One of the best characterized galectins is galectin-3, a unique member of the family being the only galectin composed of a CRD linked to a collagenlike, nonlectin N-domain. 7, 8 Galectin-3 has been implicated in a variety of physiological and pathological processes. In inflammation, galectin-3 has evolved as an important regulatory mediator, 9 shown by its capacity to promote cell adhesion, [10] [11] [12] [13] enhance phagocytosis, 14, 15 and induce production of NADPH-oxidase-derived ROS in human neutrophils. [3] [4] [5] 16 The N-domain of galectin-3 has been shown to take part in aggregation and cooperative binding of galectin-3 to glycoconjugates, 17, 18 functions that are proposed to be crucial for galectin-3-induced cell activation to occur. 19, 20 However, the collagen-like feature of the N-domain renders this part of the molecule sensitive to protease degradation. Nieminen et al. have shown that proteases, including elastase, released by primed neutrophils are able to cleave galectin-3 into truncated fragments containing the CRD but lacking the Ndomain, 21 designated galectin-3C. The property to cleave galectin-3 is displayed also by matrix metalloproteinases (MMPs) [22] [23] [24] and bacterial collagenases. 17, 19, 25 Galectin-3C is unable to induce cell activity 4, 21 and has been described as a dominant-negative form of galectin-3, 26, 27 since it can inhibit galectin-3-induced angiogenesis, 28 affect galectin-3 maintenance of the glycocalyx barrier function at the ocular surface, 29 suppress the contribution of galectin-3 to plateletinduced COX-2 overexpression in HT29 cells, 30 supress breast cancer in vivo, 27 and attenuate galectin-3-induced osteoclastogenesis. 31 The dominant negative galectin-3C has also been shown to reduce motility and invasion in ovarian cancer cells. 32 So far, the inhibitory functions of galectin-3C have not been investigated with respect to neutrophil activation, but its presence in inflamed/infected human tissue is inferred, based on that galecin-3 increases during inflammation, 33, 34 neutrophils release (galectin-3-cleaving) proteases during inflammatory processes 21 and protease-positive bacteria release proteases during infection.
We studied the interaction of galectin-3C with neutrophils, both by measuring its effect on galectin-3-induced NADPH-oxidase activation and its effect on binding of galectin-3 to the cell surface. Further, we investigated the amount of galectin-3 and galectin-3C attached to the surfaces of circulating leukocytes ex vivo. Our data demonstrate that galectin-3C indeed has the ability to inhibit galectin-3-induced ROS production in primed neutrophils. Surprisingly, however, galectin-3C potentiated the binding of galectin-3 to the surface of neutrophils, suggesting association between the CRD parts of galectin-3 and galectin-3C (so-called C-type self-association [35] [36] [37] ).
MATERIALS AND METHODS

Reagents
PD10 columns were from Pharmacia (Stockholm, Sweden) and FicollPaque gradient were from Fischer Scientific GTF AB (Gothenburg, Sweden). FITC, TNF-, lactose, isoluminol, luminol, gelatine from porcine skin and PMA were from Sigma-Aldrich (St Louis, MO, USA). 
Production and fluorescence labeling of recombinant galectin-3 and galectin-3C
Recombinant human galectin-3 and galectin-3C were produced in Escherichia coli and purified as described. 17 Briefly, after isolation of the recombinant proteins, galectin-3 and galectin-3C were kept at 4 • C in PBS (pH 7.2) containing lactose (150 mM) until applied to a gel filtration column (PD10) to remove lactose. The proteins were diluted in Krebs-Ringer phosphate buffer (KRG: pH 7.3) supplemented with Ca 2+ (1 mM) and stored at -80 • C. For some experiments, recombinant galectin-3 and galectin-3C were labeled with FITC essentially as described by Patnaik et al. 38 or with Alexa Fluor 488, or Alexa Fluor 647 microscale protein labeling kit according to the manufacturer's protocol (Molecular Probes/Invitrogen, Grand Island, NY, USA).
In solution, both galectin-3 and galectin-3C are monomeric, but they can become multimeric when encountering ligands. 37 
Isolation of neutrophils
Neutrophils from healthy blood donors were isolated from peripheral blood or buffy coats, by a standard technique based on dextran sedimentation and Ficoll-Paque gradient centrifugation. 39 After hypotonic lysis of remaining erythrocytes, the neutrophils were diluted to 5 × 10 6 cells/ml in KRG with Ca 2+ and stored on ice.
For some experiments, the neutrophils were pretreated with TNF-(10 ng/ml, 20 min, 37 • C) that induces degranulation with a concomitant upregulation of receptors from gelatinase and specific granules 16 including the galectin-3 binding proteins CD66a (CEACAM1) and CD66b (CEACAM8). 47 
Production of ROS
Neutrophil NADPH-oxidase-derived ROS was measured using a luminol/isoluminol-amplified chemiluminescence system. 40 
SDS-PAGE and Western blotting
Samples were diluted 1:1 in nonreducing sample buffer, boiled for 5 min and applied to SDS-PAGE using 12% gels. After electrophoresis, the separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes using a Tris-glycine buffer system. 44 The membranes were then blocked by incubation in PBS containing Tween (0.05%) supplemented with gelatine (1%, prior to incubation with the anti-galectin-3 antibody) or BSA (1%, prior to incubation with the anti-CRD antibody) at RT for 30 min, or overnight at 4 • C. After blocking, the membranes were washed with PBS containing Tween (0.05%) and incubated for 2 h at RT, with either rat anti-human monoclonal galectin-3 antibody (culture supernatant of the hybridoma M3/38; diluted 1:100 in blocking buffer) which binds to the N-terminal domain of galectin-3, 21 or with affinity-purified chicken polyclonal anti-human CRD antibody (2.2 g/ml in blocking buffer; produced by Capra Science, Ängelholm, Sweden). The polyclonal anti-CRD antibody was produced in chicken due to the fact that mammals show highly conserved sequences, and thus low immunogenicity, between their CRDs. 7 After incubation with antibodies, the membranes were washed and incubated for 2 h in RT with HRP-labeled anti-rat-IgG antibody (1.3 g/ml in blocking buffer) or HRP-labeled anti-chickenIgG antibody (diluted 1:5000 in blocking buffer), respectively. After additional washing, peroxidase substrate was added according to manufacturer's instructions, and luminescence was analyzed in a 
Proteolytic cleavage of galectin-3
Recombinant galectin-3 (4 M) was incubated with TNF--primed neutrophils (5 × 10 6 cells/ml in KRG) or Staphylococcus aureus (model laboratory strain 8325-4; harvested from horse blood agar plates and suspended in tryptic soy broth) at 37 • C for 2 or 18 h, respectively. Celland bacteria-free supernatants were obtained by centrifugation (15 s at 16,100 g or 1 min at 9300 g, respectively) and analyzed by Western blotting for galectin-3 and fragments thereof. Seattle, WA, USA) was used, as described by Beum et al. 46 
Flow cytometry analysis of cell-bound galectin-3 and galectin-3C using antibodies
Statistical analysis
Statistical calculations were performed in GraphPad Prism 6.0a (Graphpad Software, San Diego, CA, USA). The specific statistical tests used for different sets of experiments are stated in the respective figure legend. A P-value < 0.05 was regarded as statistically significant and is indicated by *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
RESULTS
Galectin-3, but not galectin-3C, activates neutrophils
As previously shown by us and others, galectin-3 activates the NADPH-oxidase in primed, but not resting neutrophils, 3, 4, 16, 47, 48 generating ROS released extracellularly (ecROS; Figure 1A ) as well as ROS produced and retained intracellularly (icROS; Figure 1B ). The Nterminal domain of galectin-3, described to be responsible for aggregation and cooperative binding of galectin-3 to glycoconjugates, 17, 18 was necessary for NADPH-oxidase activity to be induced, as no ROS was produced when cells were exposed to recombinant galectin-3C alone ( Figure 1A, B) . Also the -galactoside-binding activity was essential for activation with galectin-3, as the presence of Compound 1, a synthetic inhibitor of the galectin-3 carbohydrate-binding activity, 41, 42 completely abolished galectin-3-induced ROS production ( Figure 1A , B) with an IC 50 value of 400-1000 times less than the traditionally used inhibitor lactose ( Figure 1C, D) . This difference in inhibitory concentration in this cell assay is less than the 6000-fold difference in galectin-3 affinity between lactose (K d 93 M) and Compound 1 (K d 14 nM), 41, 42, 49 mainly because more of Compound 1 than simply correlated with its K d is required to inhibit at least 50% of the added galectin-3 (0.8 M). This is mathematically explained in Supplemental Figure 4 .
The galectin-3-induced ROS production was paralleled by a rise in intracellular Ca 2+ in primed neutrophils ( Figure 1E ), in agreement with a previous study by Stowell et al. 50 In line with the galectin-3-induced ROS production, the Ca 2+ response was reliant on intact galectin-3 molecules, as no Ca 2+ signal was achieved when stimulating with recombinant galectin-3C and the response was abrogated in the presence of Compound 1 ( Figure 1E ).
Galectin-3C inhibits galectin-3-induced neutrophil ROS production
Galectin-3C is by itself usually inert in biological processes, including activation of neutrophils, 4,17-20 but has been found to inhibit effects induced by galectin-3. 51 To investigate whether this is true also for galectin-3-induced activation of neutrophils, we tested whether the presence of recombinant galectin-3C could affect galectin-3-induced NADPH-oxidase activation in primed human neutrophils. TNF--primed cells were pre-incubated with galectin-3C at different concentrations for 5 min at 37 • C prior to stimulation with galectin-3 (0.4 M).
Indeed, the galectin-3-induced NADPH-oxidase response was inhibited by galectin-3C in a concentration-dependent manner (Figure 2A , B, D), at concentrations equimolar to or higher than that of galectin-3 ( Figure 2D ). This inhibitory effect was specific for galectin-3-induced ROS production and was not seen when neutrophils were stimulated with the protein kinase C agonist PMA, a well-established NADPHoxidase activator ( Figure 2C, D) . Thus, we confirm that galectin-3C can inhibit galectin-3-induced biological effects and add that this may influence neutrophil activation by galectin-3.
Galectin-3 is cleaved by neutrophil proteases as well as by S. aureus proteases, producing truncated fragments containing the CRD
The presence of galectin-3C in vivo has not been thoroughly inves- Using the anti-CRD antibody, we could confirm the finding by Nieminen et al, 21 showing that primed neutrophils cleave galectin-3 into truncated fragments containing CRD ( Figure 3C ). Furthermore, we 
Endogenous galectin-3 and galectin-3C are attached to leukocytes in circulation
Galectin-3 was first discovered as a cell surface molecule on macrophages, 52 reflecting the adsorption of circulating galectin-3 that is insensitive to Compound 1.
As shown above, the prerequisite for neutrophils to be activated by galectin-3 is that the cells have been prestimulated to become primed. 
Leukocytes can sequester large amounts of exogenously added galectin-3 and galectin-3C
In order to investigate the extent of galectin-3/galectin-3C binding capacity on leukocytes, we next incubated blood with either recombinant galectin-3 or galectin-3C before fixation and immunostaining with the anti-CRD antibody (detecting both galectin-3 and galectin-3C). All investigated leukocytes had the ability to bind both galectin-3
( Figure 5A ) and galectin-3C ( Figure 5B ) added extracellularly, and saturation of binding was reached at ∼8 M for both molecules ( Figure 5A , B). Similarly to the endogenously bound galectin-3 and/or galectin-3C, binding of the recombinant equivalents was reduced in the presence of Compound 1 ( Figure 5C ). Leukocytes stained with the antigalectin-3 antibody also showed saturated binding of galectin-3 at ∼8 M (Supplementary Figure 6A) . As expected, no increased binding was seen after incubation with galectin-3C using this antibody (Supplemental Figure 6B ). . Statistical analysis was performed using a repeated measurement one-way ANOVA, followed by Dunnet's multiple comparison test to neutrophils incubated with buffer followed by FITC-labeled galectin-3 galectin-3C, indicating that preincubation of the cells with galectin-3C before addition of galectin-3 appears to limit the interaction to type-C self-association ( Figure 6A ). The increase in binding was much higher for FITC-labeled galectin-3 in the presence of unlabeled galectin-3 ( Figure 6A ), indicating that the N-terminal domain of galectin-3 may enhance the type C-self association not only in solution 29 but also on cell surfaces, or alternatively, that the system shifts to a more pure type-N self-association.
Addition of galectin-3C increases the binding of galectin-3 to neutrophil cell surfaces
The type-C self-association on the cell surface of neutrophils was investigated in more detail by treating the neutrophils with different concentrations of recombinant unlabeled galectin-3C prior to incubation with a fixed concentration of FITC-labeled galectin-3. At equimolar concentrations of galectin-3 and galectin-3C, a significant increase of galectin-3 binding was seen on both TNF-primed ( Figure 6B) and unprimed (Supplemental Figure 7) neutrophils. The binding of galectin-3 was even more enhanced by pretreating the neutrophils with 10 times as much galectin-3C as galectin-3 and was inhibited in the presence of Compound 1 ( Figure 6B) , signifying that the type-C self-association complexes are attached to the cell surface, in a carbohydrate-dependent manner.
Galectin-3 and galectin-3C colocalize on the cell surface of leukocytes
To analyze how the associated galectin-3 and galectin-3C are distributed on the neutrophil surface, the binding pattern of recombinant fluorescently labeled galectin-3 and galectin-3C was examined using imaging flow cytometry. At equimolar concentrations, we found galectin-3 and galectin-3C to colocalize ( Figure 7A ), identified by a colocalization score equal to that of the positive control ( Figure 7B and Supplemental Figure 3 ). Unprimed and TNF-primed neutrophils displayed similar extents of colocalization for galectin-3 and galectin-3C on the cell surface, and the score was significantly increased in comparison to the negative control ( Figure 7C and Supplemental Figure 3 ). This overlap (colocalization) between galectin-3 and galectin-3C on the neutrophil cell surface gives support to the notion that the lectins are associated homo-and heterologously in networks supported by both N-and C-type self-association.
DISCUSSION
This study was initiated to perform an in detail investigation of the galectin-3C effect on the galectin-3-neutrophil interaction. Our data demonstrate that galectin-3C inhibits galectin-3-induced activation of neutrophil ROS production, but that this inhibition was not due to abrogated binding of galectin-3, as originally hypothesized. Instead, we found that leukocytes can bind large amounts of both galectin-3 and galectin-3C on the cell surface and that the presence of galectin-3C on neutrophil plasma membranes increases the binding of galectin-3, most probably by a process called type-C self-association, which seems to be a nonactivating process in contrast to type-N self-association, which seems to be necessary for neutrophil activation by galectin-3.
Galectin-3 is present in plasma of healthy humans at a concentration of ∼12 ng/ml (0.5 nM), 53, 54 and diversions from this level have emerged as a diagnostic tool in different pathologies, including cancer [55] [56] [57] and heart failure. 58, 59 However, the lectin was first discovered as a cell surface marker on mononuclear cells, 52 implying that there is both a soluble and a cell-attached pool of galectin-3 in circulating blood. We found that circulating galectin-3 is attached not only to monocytes but also to neutrophils and lymphocytes. Based on the finding that both neutrophils and bacteria can cleave galectin-3 into truncated galectin-3C forms, 17, 19, 21, 25 and that such truncated molecules have been shown to inhibit galectin-3-induced activities, 51 we also investigated the presence of endogenous galectin-3/galectin-3C attached to leukocytes in blood. By comparing the relative amount of cellular staining by an anti-CRD antibody (detecting both full-length diseases such as systemic inflammatory response syndrome(SIRS), 61, 62 autoinflammatory diseases, 48 and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis. 63 Possibly, a down-regulation of galectin-3-induced NADPH-oxidase activation could be achieved by galectin-3C in these primed cells, resulting from activity of proteases released from the same cells, a function that could be of protective value to the host.
In this study, we show that galectin-3 and galectin-3C are attached to resting neutrophils in circulation, as well as and in increased amounts to TNF-primed neutrophils. We and others have earlier shown that activation of neutrophils by galectin-3 only occurs if the cells are primed, 4, 16, 47, 48 either through in vivo transmigration 4 or in vitro prestimulation. [3] [4] [5] 16, 48 The need of priming of the cells for activation with galectin-3 is most probably due to the upregulation of (specific) receptors on primed as compared to unprimed/resting neutrophils, and earlier we have tentatively identified possible receptor candidates to be CD66a and CD66b. 47 The attachment of galectin-3
and galectin-3C to the surface of resting cells, not resulting in any cellular activation, is however intriguing. Whether these attached lectins play any role is unknown, but it has been suggested that galectin-3 takes part in neutrophil adhesion to extracellular matrix proteins and other cells. 11, 14, 64, 65 Possibly, these lectins could also be functional as blockers or enhancers of receptor signaling influencing cell activation/inactivation in circulation.
Our data on attachment of endogenous galectin-3 to the cell surface of leukocytes are in contrast to the study by Baseras et al., 66 showing no attachment of endogenous galectin-3 on neutrophils. The reason for the contradiction between our results could, for example, be the use of different antibodies, as our experience is that the specificity of different anti-galectin-3 antibodies varies considerably. Another possibility is that differences in experimental protocols may lead to different extents of galectin-3 dissociation from the cell surface during the experimental assays. However, Baseras et al. 66 showed that neutrophils display capacity to bind additional galectin-3, which agrees with our results.
As galectin-3C was found to inhibit the galectin-3-induced activation of neutrophils, we hypothesized that galectin-3C would competitively inhibit the binding of galectin-3 to neutrophils. However, galectin-3C instead potentiated the binding of galectin-3. The original dogma that galectin-3 molecules form oligomers through interactions involving the N-domain (type-N self-association 17,18,37 ) has been complemented with another galectin-3-organizational model by data demonstrating that galectin-3 molecules apart from type-N selfassociation also can form oligomers by interactions involving the CRD part of the molecules. [35] [36] [37] This novel type of association was recently named type-C self-association, 37 to distinguish it from the classical type-N self-association. The biological relevance of type-C selfassociation has so far not been elucidated, but our data demonstrating that the presence of galectin-3C increases binding of both itself and galectin-3, indicate that this mechanism not only occurs homologously but also heterologously and not only in soluble systems but also on cell surfaces.
The increase in galectin-3 binding by galectin-3C occurring in parallel to galectin-3C inhibition of galectin-3-induced neutrophil activation
indicates that the mechanism of inhibition is not simply blockade of activation receptors. However, even though the net binding of galectin-3 increases, the binding to the activation receptors may be blocked, either through specific interaction with galectin-3C, or through the alteration of lattices' structural organization covering the cell surface.
Lattice formation has been shown to form on neutrophils 18 and may play important roles in regulation of cellular function, why alteration of its structural organization influenced by varying levels of galectin-3C may be important.
In summary, galectin-3 and galectin-3C interact on the surface of neutrophils in that the attachment of one is increased by presence of the other, that is, we provide proof of principle for type-C selfassociation to occur not only in solution but also on cell surfaces. Since this increase in binding is paralleled by galectin-3C-mediated inhibition of the galectin-3-induced ROS production, type-C self-association appears to be a nonactivating process in contrast to type-N selfassociation, which is necessary for neutrophil activation by galectin-3. We speculate that type-C self-association is a "turn-off" system for galectin-3-induced ROS, with the purpose of avoiding overproduction of ROS that may cause extensive tissue damage. Galecto Biotech AB, Sweden, which develops galectin-targeting drugs.
